# WIA-PET-009 Pet Cloning Standard v2.0

**标准编号**: WIA-PET-009
**版本**: 2.0
**发布日期**: 2025-01-15
**状态**: Current
**类别**: Biotechnology / Reproductive Technology
**哲学**: 弘益人間 (Benefit All Humanity)

## Table of Contents

1. [Introduction](#1-introduction)
2. [Scope](#2-scope)
3. [Normative References](#3-normative-references)
4. [Terms and Definitions](#4-terms-and-definitions)
5. [General Requirements](#5-general-requirements)
6. [Genetic Material Collection and Preservation](#6-genetic-material-collection-and-preservation)
7. [Somatic Cell Nuclear Transfer (SCNT) Protocol](#7-somatic-cell-nuclear-transfer-scnt-protocol)
8. [Embryo Culture and Development](#8-embryo-culture-and-development)
9. [Embryo Transfer and Pregnancy Management](#9-embryo-transfer-and-pregnancy-management)
10. [Animal Welfare Requirements](#10-animal-welfare-requirements)
11. [Quality Control and Success Metrics](#11-quality-control-and-success-metrics)
12. [Ethical Requirements](#12-ethical-requirements)
13. [Legal Compliance](#13-legal-compliance)
14. [Data Security and Privacy](#14-data-security-and-privacy)
15. [Client Communication and Informed Consent](#15-client-communication-and-informed-consent)

---

## 1. Introduction

### 1.1 Purpose

This standard establishes comprehensive guidelines for pet cloning operations using somatic cell nuclear transfer (SCNT) technology. It ensures:

- Consistent, reproducible procedures across facilities
- High standards of animal welfare throughout the process
- Ethical conduct aligned with societal values
- Quality outcomes for clients
- Regulatory compliance
- Advancement of scientific knowledge

### 1.2 Philosophy: 弘益人間

The principle of 弘益人間 (hongik ingan - benefit all humanity) guides this standard, extending care and compassion to animal companions who enrich human lives. All procedures must prioritize animal welfare while serving legitimate human interests in preserving beloved pets' genetic legacies.

### 1.3 Application

This standard applies to:

- Commercial pet cloning facilities
- Research institutions performing pet cloning
- Veterinary clinics offering genetic preservation services
- Genetic banking and cryopreservation facilities
- Any organization involved in the pet cloning process

---

## 2. Scope

### 2.1 Included Species

This standard covers cloning of common companion animals:

- **Canines** (Canis lupus familiaris) - dogs
- **Felines** (Felis catus) - cats
- **Equines** (Equus ferus caballus) - horses

### 2.2 Procedures Covered

- Genetic material collection from living and deceased animals
- Cell culture establishment and characterization
- Cryopreservation and long-term storage
- Somatic cell nuclear transfer
- Embryo culture and development monitoring
- Embryo transfer to surrogates
- Pregnancy monitoring and management
- Neonatal care of cloned offspring
- Post-cloning health monitoring

### 2.3 Exclusions

This standard does NOT cover:

- Human cloning (prohibited)
- Cloning of wild or endangered species (separate standards apply)
- Genetic modification beyond cloning
- Cloning for food production
- Cloning of prohibited species under local law

---

## 3. Normative References

The following documents are referenced in this standard:

- ISO 9001:2015 - Quality Management Systems
- ISO/IEC 17025:2017 - General Requirements for Laboratory Competence
- Directive 2010/63/EU - Protection of Animals Used for Scientific Purposes (EU)
- USDA Animal Welfare Act and Regulations (US)
- Good Laboratory Practice (GLP) guidelines
- IETS Manual of the International Embryo Transfer Society

---

## 4. Terms and Definitions

### 4.1 Cloning

Asexual reproduction producing a genetically identical or nearly identical copy of an organism.

### 4.2 Somatic Cell Nuclear Transfer (SCNT)

Process of removing the nucleus from an oocyte and replacing it with the nucleus from a somatic (body) cell, resulting in an embryo genetically identical to the donor of the somatic cell.

### 4.3 Donor Animal

The original pet whose genetic material is used to create the clone.

### 4.4 Oocyte Donor

Female animal providing oocytes (egg cells) for the SCNT procedure.

### 4.5 Surrogate Mother

Female animal carrying the cloned embryo through pregnancy and giving birth.

### 4.6 Clone

Animal produced through SCNT, genetically identical or nearly identical to the donor animal.

### 4.7 Passage Number

Number of times a cell culture has been subcultured. Passage 0 (P0) is the initial culture; P1 is after first subculture, etc.

### 4.8 Cell Viability

Percentage of living cells in a population, typically assessed by dye exclusion tests.

### 4.9 DNA Integrity

Measure of DNA quality, assessing the degree of fragmentation or damage. Scored 0-1.0, with 1.0 being perfect integrity.

### 4.10 Blastocyst

Embryonic stage characterized by a fluid-filled cavity (blastocoel) and differentiation into inner cell mass and trophectoderm.

---

## 5. General Requirements

### 5.1 Facility Requirements

#### 5.1.1 Laboratory Infrastructure

Cloning facilities SHALL maintain:

- **Biosafety Level 2 (BSL-2)** laboratory minimum
- HEPA-filtered air supply and positive pressure in culture rooms
- Separate zones for: sample processing, cell culture, micromanipulation, embryo culture
- Temperature and humidity control (±1°C, ±5% RH)
- Emergency power systems with automatic switchover
- Backup generators capable of sustaining critical systems for 72 hours minimum

#### 5.1.2 Equipment Requirements

Required equipment includes:

- **Inverted microscopes** with DIC/Nomarski optics (400x minimum magnification)
- **Micromanipulation systems** with piezo-actuator capability
- **Tri-gas incubators** (O₂, CO₂, N₂ control, ±0.1% accuracy)
- **Controlled-rate freezers** for cryopreservation
- **Liquid nitrogen storage** with automated filling and monitoring
- **Electrofusion equipment** with programmable pulse parameters
- **Centrifuges** (refrigerated, variable speed)
- **Biosafety cabinets** (Class II minimum)
- **pH meters** (±0.01 pH accuracy)
- **Osmometers** (±5 mOsm accuracy)

### 5.2 Personnel Requirements

#### 5.2.1 Veterinarian of Record

Facilities SHALL employ or contract a licensed veterinarian responsible for:

- Animal health and welfare
- Medical decision-making
- Emergency care
- Regulatory compliance oversight

#### 5.2.2 Laboratory Director

A PhD-level scientist or equivalent with:

- Minimum 3 years experience in reproductive technology
- Demonstrated expertise in SCNT or related techniques
- Responsibility for protocol development and quality assurance

#### 5.2.3 Technical Staff

Embryologists and technicians SHALL have:

- Formal training in cell culture and micromanipulation
- Minimum 6 months supervised training before independent work
- Documented competency in all procedures performed
- Continuing education (minimum 20 hours annually)

### 5.3 Quality Management System

Facilities SHALL implement a quality management system addressing:

- Document control and version management
- Standard Operating Procedures (SOPs) for all procedures
- Equipment calibration and maintenance schedules
- Reagent and media quality control
- Non-conformance and corrective action procedures
- Internal audits (minimum annually)
- Management review

---

## 6. Genetic Material Collection and Preservation

### 6.1 Sample Collection from Living Animals

#### 6.1.1 Biopsy Procedure

Tissue biopsies SHALL be performed:

- **By**: Licensed veterinarian or trained technician under veterinary supervision
- **Under**: Local anesthesia minimum, sedation as appropriate
- **Sample size**: 4-6mm diameter punch biopsy, 2-3 samples preferred
- **Site**: Inner thigh, abdomen, or ear (avoid lesions, scars, or infections)
- **Aseptic technique**: Surgical preparation of site, sterile instruments
- **Post-procedure care**: Appropriate wound care, pain management, monitoring

#### 6.1.2 Sample Transport

Samples SHALL be:

- Placed immediately in sterile transport medium (DMEM + antibiotics/antimycotics)
- Maintained at 2-8°C (not frozen)
- Delivered to processing laboratory within 24-48 hours maximum
- Accompanied by chain-of-custody documentation

### 6.2 Post-Mortem Sample Collection

#### 6.2.1 Timing Requirements

Post-mortem collection MAY be performed:

- **Optimal**: Within 24 hours of death
- **Acceptable**: Up to 5 days if body refrigerated (2-8°C) continuously
- **Marginal**: 5-7 days with reduced success probability

**Critical**: Body MUST be refrigerated, NEVER frozen

#### 6.2.2 Collection Protocol

- Multiple samples from different sites (ear, abdomen, muscle)
- Sterile technique to minimize contamination
- Immediate placement in transport medium
- Expedited transport to laboratory

### 6.3 Cell Culture Establishment

#### 6.3.1 Processing Protocol

- Tissue mincing in sterile conditions
- Enzymatic digestion (collagenase, dispase)
- Cell isolation via centrifugation
- Primary culture in species-appropriate medium
- Incubation at 37-38.5°C, 5% CO₂, humidified atmosphere

#### 6.3.2 Culture Medium

- Base: DMEM or species-optimized formulation
- Supplementation: 10-15% fetal bovine serum (FBS) or serum replacement
- Antibiotics: Penicillin/streptomycin at standard concentrations
- Antimycotics: Amphotericin B or equivalent
- Optional: Growth factors, amino acid supplements

### 6.4 Quality Control Testing

Before cryopreservation, cells SHALL be tested for:

#### 6.4.1 Cell Viability
- **Method**: Trypan blue exclusion or equivalent
- **Acceptance**: >95% viable cells

#### 6.4.2 Growth Rate
- **Measurement**: Population doubling time
- **Acceptance**: 24-48 hours

#### 6.4.3 Contamination Screening
- **Tests**: Visual inspection, bacterial culture, mycoplasma PCR
- **Acceptance**: No evidence of contamination

#### 6.4.4 Karyotype Analysis
- **Frequency**: Initial culture and every 5th passage
- **Acceptance**: Normal diploid chromosome number

#### 6.4.5 DNA Integrity
- **Method**: Gel electrophoresis or automated analysis
- **Acceptance**: Integrity score >0.90

#### 6.4.6 Identity Confirmation
- **Method**: DNA fingerprinting (STR analysis or equivalent)
- **Purpose**: Verify cells match donor animal, prevent mix-ups

### 6.5 Cryopreservation

#### 6.5.1 Cell Preparation
- Harvest at 80-90% confluence, passage 2-5 preferred
- Cell concentration: 1-2 million cells/ml
- Resuspension in freezing medium (90% FBS + 10% DMSO)

#### 6.5.2 Controlled-Rate Freezing
- **Rate**: 1°C/min from 4°C to -40°C
- **Rate**: 10°C/min from -40°C to -80°C
- **Hold**: Minimum 2 hours at -80°C
- **Transfer**: To liquid nitrogen vapor phase (-196°C)

#### 6.5.3 Storage
- **Temperature**: -196°C (liquid nitrogen)
- **Monitoring**: 24/7 temperature monitoring with alarms
- **Backup**: Dual-site storage recommended
- **Labeling**: Unique identifiers, barcode/RFID tracking
- **Documentation**: Complete records of location, date, passage number

---

## 7. Somatic Cell Nuclear Transfer (SCNT) Protocol

### 7.1 Oocyte Collection

#### 7.1.1 Donor Selection
- Age: 2-6 years (species-specific)
- Proven fertility preferred
- Excellent health status
- Genetic compatibility with clone species/breed

#### 7.1.2 Ovarian Stimulation

**Canine Protocol**:
- FSH: 2-4 IU/kg BID for 5-9 days
- hCG: 500-1000 IU trigger
- Collection: 48-72 hours post-hCG

**Feline Protocol**:
- eCG: 100-150 IU single injection
- hCG: 100 IU trigger 80-84 hours later
- Collection: 24-30 hours post-hCG

#### 7.1.3 Oocyte Quality Grading

| Grade | Characteristics | SCNT Suitability |
|-------|----------------|------------------|
| A | Uniform cytoplasm, intact zona, single polar body | Optimal |
| B | Minor irregularities, intact zona | Good |
| C | Moderate defects, zona intact | Marginal |
| D | Severe defects | Reject |

**Requirement**: Use only A and B grade oocytes for SCNT

### 7.2 Enucleation

#### 7.2.1 Preparation
- Cytochalasin B treatment: 5 μg/ml, 10-15 minutes
- Transfer to manipulation medium
- Identify metaphase plate location

#### 7.2.2 Procedure
- Position oocyte with metaphase plate at 3 o'clock
- Zona penetration via piezo actuation
- Membrane penetration
- Aspiration of metaphase plate + minimal cytoplasm
- Pipette withdrawal

#### 7.2.3 Verification
- Hoechst 33342 staining of removed material (confirm DNA present)
- UV examination of enucleated oocyte (confirm no remaining DNA)

#### 7.2.4 Recovery
- Transfer to fresh medium without cytochalasin B
- Rest 30-60 minutes before fusion

### 7.3 Donor Cell Preparation

#### 7.3.1 Cell Synchronization
- Serum starvation: 0.5% FBS for 2-5 days
- Goal: Arrest cells in G0/G1 phase

#### 7.3.2 Cell Selection
- Size: 10-15 μm diameter
- Morphology: Smooth membrane, high nucleus:cytoplasm ratio
- Viability: Confirmed by exclusion staining

### 7.4 Nuclear Transfer via Electrofusion

#### 7.4.1 Couplet Formation
- Place donor cell in perivitelline space
- Ensure tight apposition to oocyte membrane

#### 7.4.2 Fusion Medium
- 0.3 M mannitol
- 0.1 mM CaCl₂
- 0.1 mM MgSO₄
- 0.01% BSA

#### 7.4.3 Electrofusion Parameters
- **Alignment**: 3-5 V AC, 5-10 seconds
- **Fusion pulse**: 1.75 kV/cm DC, 20 μsec, 2 pulses, 1-second interval
- **Post-fusion**: Immediate transfer to culture medium
- **Incubation**: 30-60 minutes
- **Assessment**: Microscopically verify fusion (donor cell incorporated)

**Acceptance**: Fusion efficiency >75%

### 7.5 Artificial Activation

#### 7.5.1 Calcium Ionophore Method
- Ionomycin: 5 μM, 5 minutes
- Wash thoroughly
- Cycloheximide: 10 μg/ml, 4 hours
- Wash and transfer to culture medium

#### 7.5.2 Alternative Methods
- Electrical activation
- Strontium chloride treatment
- Combination protocols (as validated)

---

## 8. Embryo Culture and Development

### 8.1 Culture System

#### 8.1.1 Sequential Media Protocol

**Stage 1 (Days 0-3): Cleavage Medium**
- Base: SOF or KSOM
- Glucose: 0.5 mM
- Amino acids: Essential + non-essential
- Protein: BSA 4 mg/ml

**Stage 2 (Days 4-7): Blastocyst Medium**
- Increased glucose: 3.15 mM
- Higher amino acid concentrations
- Protein: BSA 5 mg/ml or serum replacement
- ITS supplement (insulin, transferrin, selenium)

#### 8.1.2 Culture Conditions
- **Temperature**: 38.5°C (dogs/cats), 38.0°C (horses)
- **Humidity**: 95-100%
- **CO₂**: 5% (±0.1%)
- **O₂**: 5-7% (reduced from atmospheric)
- **N₂**: Balance

#### 8.1.3 Culture Format
- Microdrop culture: 20-50 μl drops under mineral oil
- Group culture: 1-5 embryos per drop
- Media change at stage transition (day 3-4)

### 8.2 Developmental Assessment

#### 8.2.1 Monitoring Schedule
- **Day 1 (24h)**: 2-cell stage expected (>85%)
- **Day 2 (48h)**: 4-cell stage
- **Day 3 (72h)**: 8-16 cell/morula
- **Day 5-6**: Cavitation begins
- **Day 6-7**: Blastocyst formation

#### 8.2.2 Quality Grading

Blastocyst grading system:

| Component | A | B | C |
|-----------|---|---|---|
| Expansion | Fully expanded | Moderate | Early cavitation |
| ICM | Prominent, compact | Visible, organized | Difficult to identify |
| TE | Many cells, cohesive | Adequate coverage | Few cells, gaps |

**Example**: AA = A-grade ICM + A-grade TE (best quality)

### 8.3 Success Metrics

Expected developmental rates:

| Stage | Canine | Feline | Equine |
|-------|--------|--------|--------|
| 2-cell | 85-90% | 90-95% | 85-90% |
| 4-cell | 75-80% | 80-85% | 75-80% |
| 8-cell | 60-70% | 70-75% | 60-70% |
| Blastocyst | 25-35% | 35-45% | 30-40% |

Facilities SHALL document actual rates and investigate if consistently below targets.

---

## 9. Embryo Transfer and Pregnancy Management

### 9.1 Surrogate Selection

#### 9.1.1 Requirements
- Age: 2-6 years, prime reproductive age
- Proven fertility (previous successful pregnancy preferred)
- Excellent health status (physical exam, bloodwork)
- Normal reproductive tract (ultrasound examination)
- Temperament: Calm, easily handled
- Body condition: Optimal (not over/underweight)
- Current vaccinations and parasite control

#### 9.1.2 Screening
- Complete physical examination
- CBC and chemistry panel
- Reproductive tract ultrasound
- Brucella testing (species-appropriate)
- Genetic disease screening (breed-specific)

### 9.2 Synchronization

Surrogate reproductive status SHALL be synchronized with embryo developmental stage:

- **Day 5-7 blastocysts** → **Day 5-7 diestrus surrogates**

#### 9.2.1 Natural Cycle Method
- Monitor for natural estrus
- Serial progesterone testing to identify ovulation
- Transfer 5-7 days post-ovulation

#### 9.2.2 Hormonal Induction
- Estrogen priming (species-specific protocol)
- Progesterone supplementation initiated 2-3 days before transfer
- Continued progesterone through at least day 35 of pregnancy

### 9.3 Surgical Embryo Transfer

#### 9.3.1 Procedure

1. **Anesthesia**: General anesthesia with appropriate monitoring
2. **Surgical approach**: Ventral midline laparotomy
3. **Uterine exposure**: Gentle exteriorization, keep moist
4. **Embryo loading**: 1-3 blastocysts in 5-10 μl medium
5. **Transfer**: 20-gauge needle puncture, catheter insertion
6. **Deposition**: Slow expulsion into uterine lumen (mid-cranial horn)
7. **Bilateral transfer**: Distribute embryos between both horns
8. **Closure**: Standard surgical closure in layers

#### 9.3.2 Post-Transfer Care
- Pain management: NSAIDs or opioids, 3-5 days
- Activity restriction: 10-14 days
- Continued progesterone (if applicable)
- Monitoring for complications

### 9.4 Pregnancy Detection and Monitoring

#### 9.4.1 Detection Methods

| Method | Timing | Reliability | Information |
|--------|--------|-------------|-------------|
| Relaxin blood test | Day 22-25 | High (95%+) | Yes/no only |
| Ultrasound | Day 18-20 | Very high (98%+) | Count, viability, heartbeat |
| Palpation | Day 28-35 | Moderate (70-80%) | Yes/no, approximate count |
| Radiography | Day 45+ | Very high | Exact count, skeletal assessment |

**Recommended**: Ultrasound at days 25-30, follow-up at days 45 and 55

#### 9.4.2 Monitoring Schedule
- Weekly ultrasound examinations
- Fetal heartbeat and movement assessment
- Placental evaluation
- Uterine environment assessment
- Early detection of complications

### 9.5 Birth and Neonatal Care

#### 9.5.1 Birth Preparation
- Expected due date calculation based on transfer date
- Veterinary availability during expected parturition window
- Monitoring for signs of labor onset
- Cesarean section readiness if indicated

#### 9.5.2 Delivery Assistance
- Natural birth preferred when uncomplicated
- Veterinary supervision recommended
- C-section performed if:
  - Dystocia (difficult birth)
  - Large offspring syndrome suspected
  - Prolonged labor without progress
  - Fetal distress detected

#### 9.5.3 Immediate Neonatal Care
- Airway clearance, breathing stimulation
- Umbilical cord management
- Temperature support (warming)
- Encourage nursing within 2-4 hours
- Colostrum intake verification
- Weight measurement, identification

---

## 10. Animal Welfare Requirements

### 10.1 General Principles

All procedures SHALL:

- Minimize pain, distress, and suffering
- Use appropriate anesthesia and analgesia
- Employ humane handling and restraint
- Provide species-appropriate housing and care
- Ensure veterinary oversight and intervention

### 10.2 Oocyte Donors

#### 10.2.1 Housing Standards
- Meets or exceeds legal requirements for species
- Socialization and environmental enrichment
- Species-appropriate group or individual housing
- Climate control, lighting (12:12 light:dark cycle)

#### 10.2.2 Procedure Limits
- **Maximum**: 4-6 collections per year
- **Minimum rest**: 60-90 days between collections
- **Annual veterinary exam**: Reproductive health assessment
- **Retirement**: After 5 years or age 8, whichever first

#### 10.2.3 Pain Management
- Appropriate sedation/anesthesia for all procedures
- Post-procedure analgesia as needed
- Monitoring during recovery

#### 10.2.4 Retirement
- Guaranteed placement: Adoption, sanctuary, or retention
- Euthanasia only for humane medical reasons
- Follow-up on placement success

### 10.3 Surrogate Mothers

#### 10.3.1 Pregnancy Limits
- **Maximum**: 3-4 surrogate pregnancies lifetime
- **Minimum interval**: 12 months between pregnancies
- No breeding before age 2 or after age 7

#### 10.3.2 Prenatal Care
- Enhanced nutrition during pregnancy
- Regular veterinary examinations (minimum monthly)
- Serial ultrasounds to monitor pregnancy
- Immediate intervention for complications

#### 10.3.3 Birth and Postpartum
- Veterinary supervision at birth
- C-section availability
- Post-partum monitoring (minimum 2 weeks)
- Lactation support as needed

#### 10.3.4 Retirement
- Same requirements as oocyte donors
- Spay recommended after final pregnancy

### 10.4 Cloned Offspring

#### 10.4.1 Neonatal Period (0-8 weeks)
- Close monitoring first 48 hours
- Adequate warmth, nutrition
- Veterinary intervention for complications
- Socialization beginning at appropriate age
- Vaccination and preventive care

#### 10.4.2 Humane Endpoints
- Clear criteria for euthanasia consideration
- Severe congenital abnormalities incompatible with quality of life
- Suffering without reasonable prospect of relief
- Decision by veterinarian, not economics alone

---

## 11. Quality Control and Success Metrics

### 11.1 Process Monitoring

Facilities SHALL track and document:

#### 11.1.1 Cell Culture Metrics
- Culture establishment success rate (target: >95%)
- Post-thaw viability (target: >90%)
- Contamination rate (target: <2%)

#### 11.1.2 SCNT Procedure Metrics
- Oocyte quality distribution (% A/B/C/D grade)
- Enucleation success rate (target: >85%)
- Fusion success rate (target: >75%)

#### 11.1.3 Embryo Development Metrics
- Cleavage rate to 2-cell (target: >85%)
- Blastocyst formation rate (species-specific targets)
- Blastocyst quality distribution

#### 11.1.4 Clinical Outcome Metrics
- Pregnancy rate per transfer (target: >40%)
- Live birth rate per pregnancy (target: >60%)
- Overall success rate per attempt (target: species-specific)

### 11.2 Reagent and Media Quality Control

#### 11.2.1 Mouse Embryo Assay (MEA)
- **Frequency**: Every media batch before use
- **Protocol**: Culture 1-cell mouse embryos to blastocyst
- **Acceptance**: >80% blastocyst development

#### 11.2.2 Endotoxin Testing
- **Method**: LAL assay or equivalent
- **Acceptance**: <0.5 EU/ml

#### 11.2.3 Physical Parameters
- **pH**: 7.2-7.4 (±0.05)
- **Osmolarity**: 280-300 mOsm (±10)

#### 11.2.4 Sterility
- Periodic bacterial/fungal culture
- Acceptance: No growth

### 11.3 Equipment Calibration

| Equipment | Calibration Frequency | Tolerance |
|-----------|----------------------|-----------|
| Incubators | Weekly verification, annual calibration | ±0.1°C, ±0.1% CO₂ |
| pH meters | Daily calibration | ±0.01 pH |
| Osmometers | Weekly calibration | ±5 mOsm |
| Centrifuges | Quarterly verification | ±50 RPM |
| Electrofusion | Monthly voltage check | ±5% |

### 11.4 Continuous Improvement

#### 11.4.1 Data Analysis
- Statistical process control charts
- Trend analysis
- Identification of factors affecting success

#### 11.4.2 Corrective Actions
- Investigation when metrics exceed control limits
- Root cause analysis for failures
- Implementation of preventive measures
- Documentation of actions and outcomes

---

## 12. Ethical Requirements

### 12.1 Institutional Ethics Review

Facilities SHALL:

- Establish or affiliate with an Institutional Animal Care and Use Committee (IACUC) or equivalent ethics review board
- Submit all protocols for ethics review before implementation
- Implement approved protocols without deviation
- Report adverse events and protocol violations
- Undergo periodic ethics audits

### 12.2 Informed Consent

#### 12.2.1 Client Education

Clients MUST be informed of:

- Clones are genetic twins, not replicas of personality/behavior
- Success rates are not 100%; multiple attempts may be needed
- Physical appearance may vary (especially coat patterns in female cats)
- Costs involved (upfront and potential additional)
- Timeline (typically 8-14 months from sample to birth)
- Risks to animals involved in the process
- Alternatives to cloning (adoption, preservation without cloning)

#### 12.2.2 Documentation

- Written informed consent signed before proceeding
- Documentation of client understanding
- Opportunity for questions and clarification
- No coercion or undue pressure

### 12.3 Prohibited Practices

Facilities SHALL NOT:

- Perform genetic modifications beyond cloning without explicit approval and additional ethics review
- Make false or misleading claims about outcomes
- Guarantee specific personality traits or behaviors
- Rush euthanasia decisions for convenience of sample collection
- Use animals for cloning if primary purpose is commercial breeding (without welfare safeguards and ethics approval)
- Proceed without informed consent

### 12.4 Transparency

Facilities SHALL:

- Publish annual reports on activities, success rates, and animal welfare metrics
- Make protocols available to regulatory authorities
- Respond honestly to client inquiries
- Disclose conflicts of interest
- Participate in industry data sharing for scientific advancement

---

## 13. Legal Compliance

### 13.1 Licensing and Registration

Facilities SHALL:

- Obtain all required federal, state, and local licenses
- Register with appropriate animal care authorities
- Maintain current veterinary practice licenses
- Renew licenses and registrations in timely manner
- Display licenses where required

### 13.2 Veterinary Practice Acts

Ensure compliance with veterinary practice acts:

- Licensed veterinarian performs or supervises procedures constituting veterinary medicine
- Veterinarian-client-patient relationship established
- Appropriate record keeping

### 13.3 Import/Export Compliance

For international operations:

- Obtain required permits for genetic material or animal transport
- Comply with CITES if applicable
- Meet health certificate and quarantine requirements
- Proper customs declarations

### 13.4 Intellectual Property

- Respect patents and licensing agreements
- Do not infringe on proprietary technologies
- Obtain appropriate licenses for patented methods

### 13.5 Data Protection

Comply with applicable data protection laws:

- GDPR (Europe)
- CCPA (California)
- Other jurisdiction-specific privacy laws

### 13.6 Record Retention

- Maintain comprehensive records for minimum 10 years
- Include: Animal records, procedure documentation, quality control data, adverse events, client communications

---

## 14. Data Security and Privacy

### 14.1 Genetic Data Protection

#### 14.1.1 Security Measures

- Encryption of stored genetic data
- Access controls and authentication
- Audit trails for all data access
- Regular security assessments
- Intrusion detection and prevention

#### 14.1.2 Backup and Redundancy

- Daily backups of critical data
- Off-site backup storage
- Disaster recovery plan
- Regular restoration testing

### 14.2 Client Privacy

- Confidentiality of client information
- Secure storage of personal data
- Limited access on need-to-know basis
- Data breach notification procedures
- Right to access, correction, deletion (where applicable)

### 14.3 Sample Tracking

- Unique identifiers for all samples
- Barcode or RFID tracking systems
- Chain of custody documentation
- Prevention of sample mix-ups or loss

---

## 15. Client Communication and Informed Consent

### 15.1 Pre-Service Communication

Clients SHALL receive:

#### 15.1.1 Educational Materials

- Explanation of cloning process
- Realistic success rate information
- Timeline expectations
- Cost breakdown
- Welfare considerations
- Limitations of cloning (behavior, personality)

#### 15.1.2 Contractual Agreement

Written contract covering:

- Services to be provided
- Costs and payment terms
- Success rate disclosures
- What happens if cloning is unsuccessful
- Ownership of genetic material and clone
- Dispute resolution procedures
- Limitation of liability clauses (within legal bounds)
- Confidentiality and privacy provisions

### 15.2 Ongoing Communication

During the process:

- Regular updates on progress
- Prompt notification of problems or delays
- Transparent communication about outcomes
- Opportunity for questions at any stage

### 15.3 Post-Cloning Support

After clone delivery:

- Health information and care recommendations
- Genetic counseling regarding predispositions
- Ongoing support availability
- Follow-up on clone's health and well-being

---

## Appendix A: Revision History

### Version 2.0 (2025-01-15) - Current
- Enhanced quality control requirements
- Added data security section
- Updated success rate targets based on current capabilities
- Expanded ethical requirements
- Added retirement requirements for oocyte donors and surrogates
- Clarified informed consent procedures

### Version 1.2 (2024-03-10)
- Added equine-specific protocols
- Enhanced embryo grading system
- Improved contamination screening requirements

### Version 1.1 (2023-06-01)
- Added cryopreservation protocols
- Enhanced quality control measures
- Clarified animal welfare requirements

### Version 1.0 (2022-01-15) - Initial Release
- Established basic SCNT protocols
- Defined general requirements
- Set minimum animal welfare standards

---

## Appendix B: Contacts

**Standard Development Organization**:
World Certification Industry Association (WIA)
Email: standards@wia-official.org
Website: https://wia-official.org

**Technical Committee**:
WIA-PET-009 Technical Committee
Email: pet-009@wia-official.org

---

**Document Status**: OFFICIAL
**Copyright**: © 2025 SmileStory Inc. / WIA
**Philosophy**: 弘益人間 (Benefit All Humanity)

---

*This standard is maintained and updated by the WIA Technical Committee. Feedback, suggestions, and reports of implementation experiences are welcomed and should be directed to pet-009@wia-official.org.*